| Case Number | 6957 |
| Request Date | 07/09/2019 |
| Completion Date | 19/09/2019 |
Details of the Request
Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the following conditions.
Treatment:
- Abatacept (Orencia)
- Adalimumab biosimilar [Amgevita]
- Adalimumab biosimilar [Hulio]
- Adalimumab [Humira]
- Adalimumab biosimilar [Hyrimoz]
- Adalimumab biosimilar [Imraldi]
- Apremilast (Otezla)
- Baricitinib (Olumiant)
- Brodalumab (Kyntheum)
- Certolizumab (Cimzia)
- Dimethyl Fumarate (Skilarence)
- Etanercept (Enbrel)
- Etanercept Biosimilar (Benepali)
- Etanercept Biosimilar (Erelzi)
- Golimumab (Simponi)
- Guselkumab (Tremfya)
- Infliximab [Flixabi]
- Infliximab [Inflectra]
- Infliximab [Remicade]
- Infliximab [Remsima]
- Ixekizumab (Taltz)
- Rituximab (Mabthera)
- Rituximab Biosimilar (Rixathon)
- Rituximab Biosimilar (Truxima)
- Sarilumab (Kevzara)
- Secukinumab (Cosentyx)
- Tildrakizumab (Ilumetri)
- Tocilizumab (Ro Actemra)
- Tofacitinib (Xeljanz)
- Ustekinumab (Stelara)
- Vedolizumab (Entyvio)
Details of the Response
The data was run between 09/18 to 08/19.
| Treatment | Total |
| Abatacept (Orencia) | 12 |
| Adalimumab biosimilar [Amgevita] | 0 |
| Adalimumab biosimilar [Hulio] | 0 |
| Adalimumab [Humira] | 304 |
| Adalimumab biosimilar [Hyrimoz] | 0 |
| Adalimumab biosimilar [Imraldi] | 191 |
| Apremilast (Otezla) | 28 |
| Baricitinib (Olumiant) | 0 |
| Brodalumab (Kyntheum) | 0 |
| Certolizumab (Cimzia) | 65 |
| Dimethyl Fumarate (Skilarence) | 3 |
| Etanercept (Enbrel) | 8 |
| Etanercept Biosimilar (Benepali) | 160 |
| Etanercept Biosimilar (Erelzi) | 0 |
| Golimumab (Simponi) | 6 |
| Guselkumab (Tremfya) | 0 |
| Infliximab [Flixabi] | 3 |
| Infliximab [Inflectra] | 102 |
| Infliximab [Remicade] | 1 |
| Infliximab [Remsima] | 0 |
| Ixekizumab (Taltz) | 3 |
| Rituximab (Mabthera) | 0 |
| Rituximab Biosimilar (Rixathon) | 0 |
| Rituximab Biosimilar (Truxima) | 27 |
| Sarilumab (Kevzara) | 0 |
| Secukinumab (Cosentyx) | 39 |
| Tildrakizumab (Ilumetri) | 0 |
| Tocilizumab (Ro Actemra) | 38 |
| Tofacitinib (Xeljanz) | 0 |
| Ustekinumab (Stelara) | 44 |
| Vedolizumab (Entyvio) | 54 |
| Treatment | Psoriasis | Crohns disease | Ulcerative Colitis |
| Abatacept (Orencia) | 12 | 0 | 0 |
| Adalimumab biosimilar [Amgevita] | 0 | 0 | 0 |
| Adalimumab biosimilar [Hulio] | 0 | 0 | 0 |
| Adalimumab [Humira] | 47 | 55 | 61 |
| Adalimumab biosimilar [Hyrimoz] | 0 | 0 | 0 |
| Adalimumab biosimilar [Imraldi] | 52 | 60 | 55 |
| Apremilast (Otezla) | 0 | 0 | 3 |
| Baricitinib (Olumiant) | 0 | 0 | 0 |
| Brodalumab (Kyntheum) | 0 | 0 | 0 |
| Certolizumab (Cimzia) | 53 | 4 | 8 |
| Dimethyl Fumarate (Skilarence) | 0 | 0 | 0 |
| Etanercept (Enbrel) | 5 | 0 | 1 |
| Etanercept Biosimilar (Benepali) | 104 | 40 | 15 |
| Etanercept Biosimilar (Erelzi) | 0 | 0 | 0 |
| Golimumab (Simponi) | 1 | 2 | 2 |
| Guselkumab (Tremfya) | 0 | 0 | 0 |
| Infliximab [Flixabi] | 0 | 0 | 0 |
| Infliximab [Inflectra] | 0 | 0 | 0 |
| Infliximab [Remicade] | 0 | 0 | 0 |
| Infliximab [Remsima] | 0 | 0 | 0 |
| Ixekizumab (Taltz) | 0 | 0 | 0 |
| Rituximab (Mabthera) | 0 | 0 | 0 |
| Rituximab Biosimilar (Rixathon) | 0 | 0 | 0 |
| Rituximab Biosimilar (Truxima) | 27 | 0 | 0 |
| Sarilumab (Kevzara) | 0 | 0 | 0 |
| Secukinumab (Cosentyx) | 0 | 11 | 5 |
| Tildrakizumab (Ilumetri) | 0 | 0 | 0 |
| Tocilizumab (Ro Actemra) | 38 | 0 | 0 |
| Tofacitinib (Xeljanz) | 0 | 0 | 0 |
| Ustekinumab (Stelara) | 0 | 0 | 6 |
| Vedolizumab (Entyvio) | 0 | 0 | 0 |
| Treatment | Psoriasis | Crohns disease | Ulcerative Colitis |
| Abatacept (Orencia) | 0 | 0 | 0 |
| Adalimumab biosimilar [Amgevita] | 0 | 0 | 0 |
| Adalimumab biosimilar [Hulio] | 0 | 0 | 0 |
| Adalimumab [Humira] | 42 | 84 | 15 |
| Adalimumab biosimilar [Hyrimoz] | 0 | 0 | 0 |
| Adalimumab biosimilar [Imraldi] | 0 | 14 | 10 |
| Apremilast (Otezla) | 25 | 0 | 0 |
| Baricitinib (Olumiant) | 0 | 0 | 0 |
| Brodalumab (Kyntheum) | 0 | 0 | 0 |
| Certolizumab (Cimzia) | 0 | 0 | 0 |
| Dimethyl Fumarate (Skilarence) | 3 | 0 | 0 |
| Etanercept (Enbrel) | 2 | 0 | 0 |
| Etanercept Biosimilar (Benepali) | 1 | 0 | 0 |
| Etanercept Biosimilar (Erelzi) | 0 | 0 | 0 |
| Golimumab (Simponi) | 0 | 0 | 1 |
| Guselkumab (Tremfya) | 0 | 0 | 0 |
| Infliximab [Flixabi] | 0 | 2 | 1 |
| Infliximab [Inflectra] | 0 | 78 | 24 |
| Infliximab [Remicade] | 0 | 1 | 0 |
| Infliximab [Remsima] | 0 | 0 | 0 |
| Ixekizumab (Taltz) | 3 | 0 | 0 |
| Rituximab (Mabthera) | 0 | 0 | 0 |
| Rituximab Biosimilar (Rixathon) | 0 | 0 | 0 |
| Rituximab Biosimilar (Truxima) | 0 | 0 | 0 |
| Sarilumab (Kevzara) | 0 | 0 | 0 |
| Secukinumab (Cosentyx) | 23 | 0 | 0 |
| Tildrakizumab (Ilumetri) | 0 | 0 | 0 |
| Tocilizumab (Ro Actemra) | 0 | 0 | 0 |
| Tofacitinib (Xeljanz) | 0 | 0 | 0 |
| Ustekinumab (Stelara) | 19 | 19 | 0 |
| Vedolizumab (Entyvio) | 0 | 25 | 29 |



